Literatur

NVL Asthma

1.   Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma - Langfassung, 2. Auflage. Version 5. 2009 [cited: 2018-09-13]. DOI: 10.6101/AZQ/000163. http://doi.org/10.6101/AZQ/000163.

2.   Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Allgemeine Methoden. Version 5.0. Köln: IQWiG; 2017. http://www.iqwig.de/download/Allgemeine-Methoden_Version-5-0.pdf.

3.   Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: Toward International Standards for Clinical Practice Guidelines. Ann Intern Med 2012; 156(7):525–31. http://www.ncbi.nlm.nih.gov/pubmed/22473437.

4.   Europarat, Verbindung der Schweizer Ärztinnen und Ärzte, Ärztliche Zentralstelle Qualitätssicherung (ÄZQ), et al. Entwicklung einer Methodik für die Ausarbeitung von Leitlinien für optimale medizinische Praxis. Empfehlung Rec (2001)13 des Europarates am 10. Oktober 2001 und Erläuterndes Memorandum. Deutschsprachige Ausgabe. Z Arztl. Fortbild. Qualitatssich. 2002; 96(Suppl III):3–60.

5.   Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl 1997; 94(33):A-2154-2155.

6.   Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006. Z Arztl. Fortbild. Qualitatssich. 2005; 99(8):468–519.

7.   Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006 + Domäne 8. 2008 [cited: 2017-06-26]. http://www.leitlinien.de/mdb/edocs/pdf/literatur/delbi-fassung-2005-2006-domaene-8-2008.pdf.

8.   Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Das AWMF-Regelwerk Leitlinien. München: Zuckschwerdt; 2012. http://www.awmf.org/leitlinien/awmf-regelwerk.html.

9.   Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Programm für Nationale VersorgungsLeitlinien - Methodenreport, 5. Auflage. Version 1. 2017 [cited: 2017-12-20]. DOI: 10.6101/AZQ/000169. http://doi.org/10.6101/AZQ/000169.

10. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma - Leitlinienreport, 3. Auflage. Version 1. 2018 [cited: 2018-09-13]. DOI: 10.6101/AZQ/000403. https://doi.org/10.6101/AZQ/000403.

11. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7:10. DOI: 10.1186/1471-2288-7-10. http://www.ncbi.nlm.nih.gov/pubmed/17302989.

12. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin. Epidemiol. 2011; 64(4):401–6. http://www.ncbi.nlm.nih.gov/pubmed/21208779.

13. Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland (ZI), Schulz M, Rössel A, et al. Auswertungen zur Diagnostik und Therapie des Asthmas (Präsentation); 2017.

14. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454):1490–7. http://www.ncbi.nlm.nih.gov/pubmed/15205295.

15. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650):924–6. http://www.ncbi.nlm.nih.gov/pubmed/18436948.

16. Dunham RB. Nominal Group Technique: A Users’ guide. Madison: Wisconsin School of Business; 1998.

17. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Nature 1998; 2(3):i-88. http://www.ncbi.nlm.nih.gov/pubmed/9561895.

18. Kopp IB, Selbmann HK, Koller M. Konsensufindung in evidenzbasierten Leitlinien - vom Mythos zur rationalen Strategie. Z Arztl. Fortbild. Qualitatssich. 2007; 101(2):89–95. DOI: 10.1016/j.zgesun.2007.01.002. http://www.ncbi.nlm.nih.gov/pubmed/17458353.

19. Global Initiative for Asthma (GINA). The Global Strategy for Asthma Management and Prevention. 2017 [cited: 2017-03-15]. http://ginasthma.org/download/317.

20. Global Initiative for Asthma (GINA). Online Appendix Global Strategy for Asthma Management and Prevention. 2017 [cited: 2017-04-13].

21. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43(2):343–73. DOI: 10.1183/09031936.00202013. http://www.ncbi.nlm.nih.gov/pubmed/24337046.

22. Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (DGP), Deutsche Atemwegsliga, Gesellschaft für Pädiatrische Pneumologie (GPP), et al. S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. 2017 [cited: 2017-12-19]. http://www.awmf.org/uploads/tx_szleitlinien/020-009l_S2k_Asthma_Diagnostik_Therapie_2017-11_1.pdf.

23. Robert Koch-Institut (RKI). Asthma bronchiale. Faktenblatt zu GEDA 2012: Ergebnisse der Studie „Gesundheit in Deutschland aktuell 2012“. 2012 (Faktenblatt) [cited: 2017-03-03]. http://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsF/Geda2012/Asthma_bronchiale.pdf?__blob=publicationFile.

24. Langen U, Schmitz R, Steppuhn H. Häufigkeit allergischer Erkrankungen in Deutschland Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56(5-6):698–706. DOI: 10.1007/s00103-012-1652-7. http://www.ncbi.nlm.nih.gov/pubmed/23703488.

25. Robert Koch-Institut. KiGGS Welle 2 – Erste Ergebnisse aus Querschnitt- und Kohortenanalysen. Journal of health monitoring 2018(1). DOI: 10.17886/RKI-GBE-2018-003. http://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsJ/Journal-of-Health-Monitoring_01_2018_KiGGS-Welle2_erste_Ergebnisse.pdf;jsessionid=B06E6EAADB75F222A208DAD3DBCD5875.1_cid298.

26. British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN). British guideline on the management of asthma. A national clinical guideline. 2016 [cited: 2016-10-11]. http://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016.

27. Deutsche Gesellschaft für Allergologie und klinische Immunologie (DGAKI), Deutsche Gesellschaft für Kinder - und Jugendmedizin (DGKJ). S3-Leitlinie Allergieprävention - Update 2014. Evidence-based and consented guideline on allergy prevention - update 2014. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI) und der Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ). 2014 [cited: 2017-04-11]. http://www.awmf.org/uploads/tx_szleitlinien/061-016l_S3_Allergiepr%C3%A4vention_2014-07.pdf.

28. Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: A meta-analysis. Allergy 2013; 68(5):569–79. DOI: 10.1111/all.12124. http://www.ncbi.nlm.nih.gov/pubmed/23590215.

29. Rix I, Hakansson K, Larsen CG, et al. Management of chronic rhinosinusitis with nasal polyps and coexisting asthma: A systematic review. Am J Rhinol. Allergy 2015; 29(3):193–201. DOI: 10.2500/ajra.2015.29.4178. http://www.ncbi.nlm.nih.gov/pubmed/25975250.

30. Glacy J, Putnam K, Godfrey S, et al. Treatments for Seasonal Allergic Rhinitis. 2013 [cited: 2017-01-04]. http://www.ncbi.nlm.nih.gov/books/NBK153714/pdf/Bookshelf_NBK153714.pdf.

31. Morales DR, Jackson C, Lipworth BJ, et al. Adverse respiratory effect of acute beta-blocker exposure in asthma: A systematic review and meta-analysis of randomized controlled trials. Chest 2014; 145(4):779–86. DOI: 10.1378/chest.13-1235. http://www.ncbi.nlm.nih.gov/pubmed/24202435.

32. Morales DR, Guthrie B, Lipworth BJ, et al. NSAID-exacerbated respiratory disease: A meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy 2015; 70(7):828–35. DOI: 10.1111/all.12629. http://www.ncbi.nlm.nih.gov/pubmed/25855099.

33. Deutsche Atemwegsliga, Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (DGP), Deutsche Gesellschaft für Arbeitsmedizin und Umweltmedizin (DGAUM). 2k-Leitlinie Spirometrie. Leitlinie 020-017. 2015 [cited: 2016-10-11]. http://www.awmf.org/uploads/tx_szleitlinien/020-017l_S2k_Spirometrie-2015-05.pdf.

34. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26(5):948–68. http://www.ncbi.nlm.nih.gov/pubmed/16264058.

35. Broekhuizen BD, Sachs AP, Moons KG, et al. Diagnostic value of oral prednisolone test for chronic obstructive pulmonary disorders. Ann Fam Med 2011; 9(2):104–9. DOI: 10.1370/afm.1223. http://www.ncbi.nlm.nih.gov/pubmed/21403135.

36. Luisi F, Pinto LA, Marostica L, et al. Persistent pulmonary function impairment in children and adolescents with asthma. J Bras Pneumol. 2012; 38(2):158–66. http://www.ncbi.nlm.nih.gov/pubmed/22576422.

37. Riaño Pérez A, Pérez de Llano LA, Mengual N, et al. Clinical significance of the oral corticosteroid reversibility test in asthma with fixed airflow obstruction [Article in Spanish]. Arch Bronconeumol 2017; 53(1):40. DOI: 10.1016/j.arbres.2016.07.002. http://www.ncbi.nlm.nih.gov/pubmed/27484463.

38. Schneider A, Schwarzbach J, Faderl B, et al. Whole-Body Plethysmography in Suspected Asthma: A Prospective Study of Its Added Diagnostic Value in 302 Patients. Dtsch Arztebl Int 2015; 112(24):405–11. DOI: 10.3238/arztebl.2015.0405. http://www.ncbi.nlm.nih.gov/pubmed/26159217.

39. Guo Z, Wang Y, Xing G, et al. Diagnostic accuracy of fractional exhaled nitric oxide in asthma: A systematic review and meta-analysis of prospective studies. J Asthma 2016:1–9. DOI: 10.3109/02770903.2015.1101132. http://www.ncbi.nlm.nih.gov/pubmed/26796787.

40. Li Z, Qin W, Li L, et al. Diagnostic accuracy of exhaled nitric oxide in asthma: A meta-analysis of 4,691 participants. Int J Clin Exp Med 2015; 8(6):8516–24. http://www.ncbi.nlm.nih.gov/pubmed/26309503.

41. Harnan SE, Tappenden P, Essat M, et al. Measurement of exhaled nitric oxide concentration in asthma: A systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath. Health Technol Assess 2015; 19(82):1–330. DOI: 10.3310/hta19820. http://www.ncbi.nlm.nih.gov/pubmed/26484874.

42. Karrasch S, Linde K, Rucker G, et al. Accuracy of FENO for diagnosing asthma: A systematic review. Thorax 2017; 72(2):109–16. DOI: 10.1136/thoraxjnl-2016-208704. http://www.ncbi.nlm.nih.gov/pubmed/27388487.

43. Tang S, Xie Y, Yuan C, et al. Fractional Exhaled Nitric Oxide for the Diagnosis of Childhood Asthma: A Systematic Review and Meta-analysis. Clin Rev Allergy Immunol 2016:[Epub ahead of print]. DOI: 10.1007/s12016-016-8573-4. http://www.ncbi.nlm.nih.gov/pubmed/27444490.

44. Wang Z, Pianosi P, Keogh K, et al. The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. 2017 (AHRQ Publication; 17(18)-EHC030-EF) [cited: 2018-05-28]. DOI: 10.23970/AHRQEPCCER197. http://effectivehealthcare.ahrq.gov/sites/default/files/pdf/cer-197-fractional-exhaled-nitric-oxide.pdf.

45. Price DB, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: A randomised controlled trial. Lancet Respir Med 2018; 6(1):29–39. DOI: 10.1016/S2213-2600(17)30424-1. http://www.ncbi.nlm.nih.gov/pubmed/29108938.

46. Murray C, Foden P, Lowe L, et al. Diagnosis of asthma in symptomatic children based on measures of lung function: An analysis of data from a population-based birth cohort study. The lancet child & adolescent health 2017; 1(2):114–23. DOI: 10.1016/S2352-4642(17)30008-1. http://www.ncbi.nlm.nih.gov/pubmed/29034296.

47. Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: A systematic review and meta-analysis. Lancet Respir Med 2015; 3(4):290–300. DOI: 10.1016/S2213-2600(15)00050-8. http://www.ncbi.nlm.nih.gov/pubmed/25801413.

48. Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: A UK cohort study. Lancet Respir Med 2015; 3(11):849–58. DOI: 10.1016/S2213-2600(15)00367-7. http://www.ncbi.nlm.nih.gov/pubmed/26493938.

49. Aaron SD, Vandemheen KL, Fitzgerald JM, et al. Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma. JAMA 2017; 317(3):269–79. DOI: 10.1001/jama.2016.19627. http://www.ncbi.nlm.nih.gov/pubmed/28114551.

50. Deutsche Atemwegsliga, Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (DGP), Deutsche Gesellschaft für Arbeitsmedizin und Umweltmedizin (DGAUM). Leitlinienreport für die S2k-Leitlinie Spirometrie 020/017. 2015 [cited: 2016-10-11]. http://www.awmf.org/uploads/tx_szleitlinien/020-017m_S2k_Spirometrie-2015-05.pdf.

51. Leitliniengruppe Hessen, Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM), PMV forschungsgruppe, et al. Hausärztliche Leitlinie Multimedikation. Empfehlungen zum Umgang mit Multimedikation bei Erwachsenen und geriatrischen Patienten, 1. Auflage. Version 1.09. 2014 [cited: 2017-04-10]. http://www.awmf.org/uploads/tx_szleitlinien/053-043l_S2e_Multimedikation_2014-05.pdf.

52. Alshabanat A, Zafari Z, Albanyan O, et al. Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis. PLoS. One. 2015; 10(9):e0136065. DOI: 10.1371/journal.pone.0136065. http://www.ncbi.nlm.nih.gov/pubmed/26336076.

53. Ducharme FM, Ni CM, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010(5):CD005535. DOI: 10.1002/14651858.CD005535.pub2. http://www.ncbi.nlm.nih.gov/pubmed/20464739.

54. Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev 2013; 2:CD009611. DOI: 10.1002/14651858.CD009611.pub3. http://www.ncbi.nlm.nih.gov/pubmed/23450606.

55. Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2014; 1:CD003137. DOI: 10.1002/14651858.CD003137.pub5. http://www.ncbi.nlm.nih.gov/pubmed/24459050.

56. Ahmad S, Kew KM, Normansell R. Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids. Cochrane Database Syst Rev 2015; 6:CD011306. DOI: 10.1002/14651858.CD011306.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26089258.

57. Jia CE, Zhang HP, Lv Y, et al. The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis. J Allergy Clin Immunol. 2013; 131(3):695–703. DOI: 10.1016/j.jaci.2012.08.023. http://www.ncbi.nlm.nih.gov/pubmed/23058645.

58. Gionfriddo MR, Hagan JB, Hagan CR, et al. Stepping down inhaled corticosteroids from scheduled to as needed in stable asthma: Systematic review and meta-analysis. Allergy Asthma Proc. 2015; 36(4):262–7. DOI: 10.2500/aap.2015.36.3850. http://www.ncbi.nlm.nih.gov/pubmed/26108083.

59. Hagan JB, Samant SA, Volcheck GW, et al. The risk of asthma exacerbation after reducing inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials. Allergy 2014; 69(4):510–6. DOI: 10.1111/all.12368. http://www.ncbi.nlm.nih.gov/pubmed/24571355.

60. Rank MA, Hagan JB, Park MA, et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013; 131(3):724–9. DOI: 10.1016/j.jaci.2012.11.038. http://www.ncbi.nlm.nih.gov/pubmed/23321206.

61. Petsky HL, Cates CJ, Li A, et al. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2009(4):CD006340. DOI: 10.1002/14651858.CD006340.pub3. http://www.ncbi.nlm.nih.gov/pubmed/19821360.

62. Petsky HL, Kew KM, Turner C, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev 2016; 9:CD011440. DOI: 10.1002/14651858.CD011440.pub2. http://www.ncbi.nlm.nih.gov/pubmed/27580628.

63. Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database Syst Rev 2016; 11:CD011439. DOI: 10.1002/14651858.CD011439.pub2. http://www.ncbi.nlm.nih.gov/pubmed/27825189.

64. Bundesministerium der Justiz und für Verbraucherschutz (BMJV). § 630e Aufklärungspflichten. In: Bundesministerium der Justiz und für Verbraucherschutz (BMJV), editor. Bürgerliches Gesetzbuch (BGB); 2017.

65. Engelkes M, Janssens HM, Jongste JC de, et al. Medication adherence and the risk of severe asthma exacerbations: A systematic review. Eur Respir J 2015; 45(2):396–407. DOI: 10.1183/09031936.00075614. http://www.ncbi.nlm.nih.gov/pubmed/25323234.

66. Kew KM, Malik P, Aniruddhan K, et al. Shared decision-making for people with asthma. Cochrane Database Syst Rev 2017; 10:CD012330. DOI: 10.1002/14651858.CD012330.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28972652.

67. Elwyn G, Edwards A, Mowle S, et al. Measuring the involvement of patients in shared decision-making: A systematic review of instruments. Patient Educ Couns. 2001; 43(1):5–22. http://www.ncbi.nlm.nih.gov/pubmed/11311834.

68. Härter M, Loh A, Spies C. Gemeinsam entscheiden-erfolgreich behandeln. Neue Wege für Ärzte und Patienten im Gesundheitswesen. Köln: Dt. Ärzte-Verl.; 2005.

69. Loh A, Simon D, Kriston L, et al. Patientenbeteiligung bei medizinischen Entscheidungen - Effekte der Partizipativen Entscheidungsfindung aus systematischen Reviews. Dtsch Arztebl 2007; 104:A-1483-88.

70. Deutsches Netzwerk Evidenzbasierte Medizin (DNEbM). Gute Praxis Gesundheitsinformation. Ein Positionspapier des Deutschen Netzwerks Evidenzbasierte Medizin. Version 2.0. 2016 [cited: 2018-02-07]. http://www.ebm-netzwerk.de/pdf/publikationen/gpgi2.pdf.

71. Deutsches Netzwerk Evidenzbasierte Medizin (DNEbM). Gute Praxis Gesundheitsinformation. Liste der Unterzeichner. 2016 [cited: 2018-02-07]. http://www.ebm-netzwerk.de/pdf/publikationen/gpgi-unterzeichner.pdf.

72. Gemeinsamer Bundesausschuss (G-BA). Anwendung eines Arzneimittels außerhalb der genehmigten Anwendungsgebiete (Off-Label-Use). 2015 [cited: 2018-03-01]. http://www.g-ba.de/institution/themenschwerpunkte/arzneimittel/off-label-use.

73. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012(5):CD002314. DOI: 10.1002/14651858.CD002314.pub3. http://www.ncbi.nlm.nih.gov/pubmed/22592685.

74. Chauhan BF, Chartrand C, Ni CM, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2015; 11:CD007949. DOI: 10.1002/14651858.CD007949.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26594816.

75. Chauhan BF, Ben SR, Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma. Cochrane Database Syst Rev 2013; 10:CD009585. DOI: 10.1002/14651858.CD009585.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24089325.

76. Kew KM, Evans DJ, Allison DE, et al. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database Syst Rev 2015; 6:CD011438. DOI: 10.1002/14651858.CD011438.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26031392.

77. Levenson M. Long-Acting Beta-Agonists and Adverse Asthma Events Meta-Analysis. Statistical Briefing Package for Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory committee on December 10-11, 2008. 2008 [cited: 2017-09-19]. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf.

78. Food and Drug Administration (FDA). FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). 2010 [cited: 2018-08-30].

79. Kew KM, Karner C, Mindus SM, et al. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 2013; 12:CD009019. DOI: 10.1002/14651858.CD009019.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24343671.

80. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev 2013; 4:CD007313. DOI: 10.1002/14651858.CD007313.pub3. http://www.ncbi.nlm.nih.gov/pubmed/23633340.

81. Cates CJ, Lasserson TJ. Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst Rev 2009(1):CD007085. DOI: 10.1002/14651858.CD007085.pub2. http://www.ncbi.nlm.nih.gov/pubmed/19160317.

82. Kirkland SW, Vandenberghe C, Voaklander B, et al. Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma. Cochrane Database Syst Rev 2017; 1:CD001284. DOI: 10.1002/14651858.CD001284.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28076656.

83. Vezina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database Syst Rev 2014; 7:CD010283. DOI: 10.1002/14651858.CD010283.pub2. http://www.ncbi.nlm.nih.gov/pubmed/25080126.

84. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev 2013; 8:CD000060. DOI: 10.1002/14651858.CD000060.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23966133.

85. Teoh L, Cates CJ, Hurwitz M, et al. Anticholinergic therapy for acute asthma in children. Cochrane Database Syst Rev 2012(4):CD003797. DOI: 10.1002/14651858.CD003797.pub2. http://www.ncbi.nlm.nih.gov/pubmed/22513916.

86. Zhang HP, Jia CE, Lv Y, et al. Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis. Allergy Asthma Proc. 2014; 35(4):278–87. DOI: 10.2500/aap.2014.35.3745. http://www.ncbi.nlm.nih.gov/pubmed/24992547.

87. Chong J, Haran C, Chauhan BF, et al. Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults. Cochrane Database Syst Rev 2015; 7:CD011032. DOI: 10.1002/14651858.CD011032.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26197430.

88. O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med 2018; 378(20):1865–76. DOI: 10.1056/NEJMoa1715274. http://www.ncbi.nlm.nih.gov/pubmed/29768149.

89. Bateman ED, Reddel HK, O’Byrne PM, et al. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med 2018; 378(20):1877–87. DOI: 10.1056/NEJMoa1715275. http://www.ncbi.nlm.nih.gov/pubmed/29768147.

90. Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: Effects on growth. Cochrane Database Syst Rev 2014; 7:CD009471. DOI: 10.1002/14651858.CD009471.pub2. http://www.ncbi.nlm.nih.gov/pubmed/25030198.

91. Pruteanu AI, Chauhan BF, Zhang L, et al. Inhaled corticosteroids in children with persistent asthma: Dose-response effects on growth. Cochrane Database Syst Rev 2014; 7:CD009878. DOI: 10.1002/14651858.CD009878.pub2. http://www.ncbi.nlm.nih.gov/pubmed/25030199.

92. Loke YK, Gilbert D, Thavarajah M, et al. Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: Systematic review and meta-analysis. Clin Rev Allergy Immunol. 2015; 5(11):e008554. DOI: 10.1136/bmjopen-2015-008554. http://www.ncbi.nlm.nih.gov/pubmed/26603243.

93. Ducharme FM, Ni CM, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev 2010(4):CD005533. DOI: 10.1002/14651858.CD005533.pub2. http://www.ncbi.nlm.nih.gov/pubmed/20393943.

94. Ni CM, Greenstone I, Lasserson TJ, et al. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev 2009(4):CD005307. DOI: 10.1002/14651858.CD005307.pub2. http://www.ncbi.nlm.nih.gov/pubmed/19821344.

95. Cates CJ, Jaeschke R, Schmidt S, et al. Regular treatment with formoterol and inhaled steroids for chronic asthma: Serious adverse events. Cochrane Database Syst Rev 2013; 6:CD006924. DOI: 10.1002/14651858.CD006924.pub3. http://www.ncbi.nlm.nih.gov/pubmed/23744625.

96. Cates CJ, Jaeschke R, Schmidt S, et al. Regular treatment with salmeterol and inhaled steroids for chronic asthma: Serious adverse events. Cochrane Database Syst Rev 2013; 3:CD006922. DOI: 10.1002/14651858.CD006922.pub3. http://www.ncbi.nlm.nih.gov/pubmed/23543548.

97. Peters SP, Bleecker ER, Canonica GW, et al. Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone. N Engl J Med 2016; 375(9):850–60. DOI: 10.1056/NEJMoa1511190. http://www.ncbi.nlm.nih.gov/pubmed/27579635.

98. Stempel DA, Raphiou IH, Kral KM, et al. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. N Engl J Med 2016; 374(19):1822–30. DOI: 10.1056/NEJMoa1511049. http://www.ncbi.nlm.nih.gov/pubmed/26949137.

99. Stempel DA, Szefler SJ, Pedersen S, et al. Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma. N Engl J Med 2016; 375(9):840–9. DOI: 10.1056/NEJMoa1606356. http://www.ncbi.nlm.nih.gov/pubmed/27579634.

100.     Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: Serious adverse events. Cochrane Database Syst Rev 2010(1):CD007694. http://www.ncbi.nlm.nih.gov/pubmed/20091646.

101.     Hernandez G, Avila M, Pont A, et al. Long-acting beta-agonists plus inhaled corticosteroids safety: A systematic review and meta-analysis of non-randomized studies. Respir Res 2014; 15:83. DOI: 10.1186/1465-9921-15-83. http://www.ncbi.nlm.nih.gov/pubmed/25038591.

102.     Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA requires post-market safety trials for Long-Acting Beta-Agonists (LABAs). 2011 [cited: 2017-09-19]. http://www.fda.gov/Drugs/DrugSafety/ucm251512.htm.

103.     Novartis Pharmaceutical. Study of Safety of Foradil in Patients With Persistent Asthma. NCT01845025. 2013 [cited: 2017-06-27]. http://clinicaltrials.gov/ct2/show/study/NCT01845025?term=nct01845025&rank=1.

104.     U.S. Food and Drug Administration (FDA). FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS). 2017 [cited: 2018-02-22]. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM589997.pdf.

105.     Evans DJ, Kew KM, Anderson DE, et al. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. Cochrane Database Syst Rev 2015; 7:CD011437. DOI: 10.1002/14651858.CD011437.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26196545.

106.     Schwabe U, Paffrath D. Arzneiverordnungs-Report 2016. Aktuelle Daten, Kosten, Trends und Kommentare. Berlin: Springer; 2016.

107.     Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev 2016; 1:CD011721. DOI: 10.1002/14651858.CD011721.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26798035.

108.     Rodrigo GJ, Castro-Rodriguez JA. Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma: A systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2015; 115(3):211–6. DOI: 10.1016/j.anai.2015.06.029. http://www.ncbi.nlm.nih.gov/pubmed/26231467.

109.     Hamelmann E, Bateman ED, Vogelberg C, et al. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial. J Allergy Clin Immunol. 2016; 138(2):441–50. DOI: 10.1016/j.jaci.2016.01.011. http://www.ncbi.nlm.nih.gov/pubmed/26960245.

110.     Boehringer Ingelheim Pharma GmbH & Co. KG, Pfizer Inc. Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma. NCT01634139. 2012 [cited: 2017-06-14]. http://www.clinicaltrials.gov/show/NCT01634139.

111.     Vrijlandt EJ, El Azzi G, Vandewalker M, et al. Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: A randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2018; 6(2):127–37. DOI: 10.1016/S2213-2600(18)30012-2. http://www.ncbi.nlm.nih.gov/pubmed/29361462.

112.     Turner S, Richardson K, Murray C, et al. Long-Acting β-Agonist in Combination or Separate Inhaler as Step-Up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids. J Allergy Clin Immunol 2017; 5(1):99-106.e3. DOI: 10.1016/j.jaip.2016.06.009. http://www.ncbi.nlm.nih.gov/pubmed/27421902.

113.     Vedel-Krogh S, Fallgaard NS, Lange P, et al. Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study. Clin Chem 2017; 63(4):823–32. DOI: 10.1373/clinchem.2016.267450. http://www.ncbi.nlm.nih.gov/pubmed/28209625.

114.     Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187(8):804–11. DOI: 10.1164/rccm.201208-1414OC. http://www.ncbi.nlm.nih.gov/pubmed/23471469.

115.     Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1:CD003559. DOI: 10.1002/14651858.CD003559.pub4. http://www.ncbi.nlm.nih.gov/pubmed/24414989.

116.     Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: A systematic review and economic evaluation. Health Technol Assess 2013; 17(52):1–342. DOI: 10.3310/hta17520. http://www.ncbi.nlm.nih.gov/pubmed/24267198.

117.     Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol. 2015; 26(6):551–6. DOI: 10.1111/pai.12405. http://www.ncbi.nlm.nih.gov/pubmed/25963882.

118.     Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: A systematic review and meta-analysis. Sci Rep 2015; 5:8191. DOI: 10.1038/srep08191. http://www.ncbi.nlm.nih.gov/pubmed/25645133.

119.     European Medicines Agency (EMA). Xolair Omalizumab. Product information. 2016 [cited: 2017-07-13]. http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf.

120.     Warnung vor Anaphylaxie durch Asthmamittel Omalizumab (Xolair). Arznei-Telegramm 2007; 38(7):71.

121.     Kardiovaskuläre Nebenwirkungen unter Omalizumab (Xolair). Arznei-Telegramm 2009; 40(8):76.

122.     Powell C, Milan SJ, Dwan K, et al. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev 2015; 7:CD010834. DOI: 10.1002/14651858.CD010834.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26214266.

123.     Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371(13):1189–97. DOI: 10.1056/NEJMoa1403291. http://www.ncbi.nlm.nih.gov/pubmed/25199060.

124.     Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3(5):355–66. DOI: 10.1016/S2213-2600(15)00042-9. http://www.ncbi.nlm.nih.gov/pubmed/25736990.

125.     Corren J, Weinstein S, Janka L, et al. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. Chest 2016; 150(4):799–810. DOI: 10.1016/j.chest.2016.03.018. http://www.ncbi.nlm.nih.gov/pubmed/27018175.

126.     Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest 2016; 150(4):789–98. DOI: 10.1016/j.chest.2016.03.032. http://www.ncbi.nlm.nih.gov/pubmed/27056586.

127.     Fitzgerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388(10056):2128–41. DOI: 10.1016/S0140-6736(16)31322-8. http://www.ncbi.nlm.nih.gov/pubmed/27609406.

128.     Bleecker ER, Fitzgerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388(10056):2115–27. DOI: 10.1016/S0140-6736(16)31324-1. http://www.ncbi.nlm.nih.gov/pubmed/27609408.

129.     Ferguson GT, FitzGerald JM, Bleecker ER, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2017; 5(7):568–76. DOI: 10.1016/S2213-2600(17)30190-X. http://www.ncbi.nlm.nih.gov/pubmed/28545978.

130.     Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med 2017; 376(25):2448–58. DOI: 10.1056/NEJMoa1703501. http://www.ncbi.nlm.nih.gov/pubmed/28530840.

131.     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Mepolizumab - Nutzenbewertung gemäβ § 35a SGB V. 2016 (IQWiG-Berichte; 385) [cited: 2017-06-27]. http://www.g-ba.de/downloads/92-975-1333/2016-05-02_A16-03_Mepolizumab_Nutzenbewertung-35a-SGB-V.pdf.

132.     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Mepolizumab (Asthma) - Addendum zum Auftrag A16-03. 2016 (IQWiG-Berichte; 407) [cited: 2017-06-27]. http://www.g-ba.de/downloads/92-975-1434/2016-07-21_AM-RL-XII_Mepolizumab_D-211_Addendum.pdf.

133.     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Reslizumab (Asthma) - Nutzenbewertung gemäβ § 35a SGB V. 2017 (IQWiG-Berichte; 505) [cited: 2017-06-27]. http://www.g-ba.de/downloads/92-975-1778/2017-01-15_Nutzenbewertung-IQWiG_Reslizumab-D-271.pdf.

134.     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Reslizumab (Asthma) - Addendum zum Auftrag A17-02. 2017 (IQWiG-Berichte; 516) [cited: 2017-07-10]. http://www.g-ba.de/downloads/92-975-1849/2017-07-06_AM-RL-XII_Reslizumab_D-271_Addendum.pdf.

135.     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Benralizumab (Asthma) – Nutzenbewertung gemäβ § 35a SGB V. 2018 (IQWiG-Berichte; 625) [cited: 2017-06-14]. http://www.iqwig.de/download/A18-11_Benralizumab_Nutzenbewertung-35a-SGB-V_V1-0.pdf.

136.     Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V - Mepolizumab. 2016 [cited: 2017-06-27]. http://www.g-ba.de/downloads/39-261-2653/2016-07-21_AM-RL-XII_Mepolizumab_D-211_BAnz.pdf.

137.     Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V - Reslizumab. 2017 [cited: 2017-07-10]. http://www.g-ba.de/downloads/39-261-2998/2017-07-06_AM-RL-XII_Reslizumab_D-271.pdf.

138.     Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V – Benralizumab. 2018 [cited: 2018-08-20]. http://www.g-ba.de/downloads/39-261-3436/2018-08-02_AM-RL-XII_Benralizumab_D-341.pdf.

139.     Lugogo N, Domingo C, Chanez P, et al. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clin Ther 2016; 38(9):2058–70. DOI: 10.1016/j.clinthera.2016.07.010. http://www.ncbi.nlm.nih.gov/pubmed/27553751.

140.     European Medicines Agency (EMA). Assessment report. Nucala International non-proprietary name: Mepolizumab. Procedure No. EMEA/H/C/003860/0000. 2015 [cited: 2017-06-27]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003860/WC500198038.pdf.

141.     European Medicines Agency (EMA). Assessment report. Cinqaero International non-proprietary name: Reslizumab. Procedure No. EMEA/H/C/003912/0000. 2016 [cited: 2017-06-27]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003912/WC500212252.pdf.

142.     European Medicines Agency (EMA). Fasenra. international non-proprietary name: benralizumab. assessment report. 2017 [cited: 2018-04-26]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004433/WC500245333.pdf.

143.     Szefler SJ, Murphy K, Harper TI, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017; 140(5):1277–87. DOI: 10.1016/j.jaci.2017.01.014. http://www.ncbi.nlm.nih.gov/pubmed/28189771.

144.     Hamelmann E, Bernstein JA, Vandewalker M, et al. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J 2017; 49(1):1601100. DOI: 10.1183/13993003.01100-2016. http://www.ncbi.nlm.nih.gov/pubmed/27811070.

145.     Lu Y, Xu L, Xia M, et al. The efficacy and safety of subcutaneous immunotherapy in mite-sensitized subjects with asthma: A meta-analysis. Respir Care 2015; 60(2):269–78. DOI: 10.4187/respcare.03399. http://www.ncbi.nlm.nih.gov/pubmed/25389355.

146.     Lin SY, Erekosima N, Suarez-Cuervo C, et al. Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma: Comparative Effectiveness Review. 2013 [cited: 2017-01-04]. http://www.ncbi.nlm.nih.gov/books/NBK133240/pdf/Bookshelf_NBK133240.pdf.

147.     Normansell R, Kew KM, Bridgman AL. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev 2015; 8:CD011293. DOI: 10.1002/14651858.CD011293.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26315994.

148.     Liao W, Hu Q, Shen LL, et al. Sublingual Immunotherapy for Asthmatic Children Sensitized to House Dust Mite: A Meta-Analysis. Medicine (Baltimore) 2015; 94(24):e701. DOI: 10.1097/MD.0000000000000701. http://www.ncbi.nlm.nih.gov/pubmed/26091451.

149.     Larenas-Linnemann D, Blaiss M, van Bever HP, et al. Pediatric sublingual immunotherapy efficacy: Evidence analysis, 2009-2012. Ann Allergy Asthma Immunol. 2013; 110(6):402–15. DOI: 10.1016/j.anai.2013.02.017. http://www.ncbi.nlm.nih.gov/pubmed/23706708.

150.     Pfaar O, Bachert C, Bufe A, et al. Leitlinie zur (allergen-)spezischen Immuntherapie bei IgE-vermittelten allergischen Erkrankungen. S2k-Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), des Ärzteverbandes Deutscher Allergologen (AeDA), der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI), der Schweizerischen Gesellschaft für Allergologie und Immunologie (SGAI), der Deutschen Dermatologischen Gesellschaft (DDG), der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNO-KHC), der Deutschen Gesellschaft für Kinder und Jugendmedizin (DGKJ), der Gesellschaft für Pädiatrische Pneumologie (GPP), der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP), des Deutschen Berufsverbandes der HNO-Ärzte (BV-HNO), des Berufsverbandes der Kinder- und Jugendärzte (BVKJ), des Bundesverbandes der Pneumologen (BDP) und des Berufsverbandes der Deutschen Dermatologen (BVDD). Allergo. J Int 2014; 23(8):282–319. DOI: 10.1007/s40629-014-0032-2. http://www.ncbi.nlm.nih.gov/pubmed/26120539.

151.     Kircher W. Arzneiformen richtig anwenden: Sachgerechte Anwendung und Aufbewahrung der Arzneimittel. 4th ed. Stuttgart: Dt. Apotheker-Verl.; 2016.

152.     Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2013; 9:CD000052. DOI: 10.1002/14651858.CD000052.pub3. http://www.ncbi.nlm.nih.gov/pubmed/24037768.

153.     Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. Cochrane Database Syst Rev 2017; 3:CD012286. DOI: 10.1002/14651858.CD012286.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28288272.

154.     Gillette C, Rockich-Winston N, Kuhn JA, et al. Inhaler Technique in Children With Asthma: A Systematic Review. Acad Pediatr 2016; 16(7):605–15. DOI: 10.1016/j.acap.2016.04.006. http://www.ncbi.nlm.nih.gov/pubmed/27130811.

155.     Doyle S, Lloyd A, Williams A, et al. What happens to patients who have their asthma device switched without their consent? Prim Care Respir J 2010; 19(2):131–9. DOI: 10.4104/pcrj.2010.00009. http://www.ncbi.nlm.nih.gov/pubmed/20174771.

156.     Thomas M, Price D, Chrystyn H, et al. Inhaled corticosteroids for asthma: Impact of practice level device switching on asthma control. BMC Pulm Med 2009; 9:1. DOI: 10.1186/1471-2466-9-1. http://www.ncbi.nlm.nih.gov/pubmed/19121204.

157.     Ekberg-Jansson A, Svenningsson I, Ragdell P, et al. Budesonide inhaler device switch patterns in an asthma population in Swedish clinical practice (ASSURE). Int J Clin Pract 2015; 69(10):1171–8. DOI: 10.1111/ijcp.12685. http://www.ncbi.nlm.nih.gov/pubmed/26234385.

158.     Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2013; 2:CD000364. DOI: 10.1002/14651858.CD000364.pub4. http://www.ncbi.nlm.nih.gov/pubmed/23450529.

159.     Andersohn F, Bornemann R, Damm O, et al. Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment. GMS Health Technol Assess 2014; 10:Doc03. DOI: 10.3205/hta000119. http://www.ncbi.nlm.nih.gov/pubmed/25371764.

160.     Vasileiou E, Sheikh A, Butler C, et al. Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis. Clin Infect Dis 2017; 65(8):1388–95. DOI: 10.1093/cid/cix524. http://www.ncbi.nlm.nih.gov/pubmed/28591866.

161.     Carson KV, Chandratilleke MG, Picot J, et al. Physical training for asthma. Cochrane Database Syst Rev 2013; 9:CD001116. DOI: 10.1002/14651858.CD001116.pub4. http://www.ncbi.nlm.nih.gov/pubmed/24085631.

162.     Eichenberger PA, Diener SN, Kofmehl R, et al. Effects of exercise training on airway hyperreactivity in asthma: A systematic review and meta-analysis. Sports Med 2013; 43(11):1157–70. DOI: 10.1007/s40279-013-0077-2. http://www.ncbi.nlm.nih.gov/pubmed/23846823.

163.     Pakhale S, Luks V, Burkett A, et al. Effect of physical training on airway inflammation in bronchial asthma: A systematic review. BMC Pulm Med 2013; 13:38. DOI: 10.1186/1471-2466-13-38. http://www.ncbi.nlm.nih.gov/pubmed/23758826.

164.     Cramer H, Posadzki P, Dobos G, et al. Yoga for asthma: A systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2014; 112(6):503–10. DOI: 10.1016/j.anai.2014.03.014. http://www.ncbi.nlm.nih.gov/pubmed/24726198.

165.     Grande AJ, Silva V, Andriolo BN, et al. Water-based exercise for adults with asthma. Cochrane Database Syst Rev 2014; 7:CD010456. DOI: 10.1002/14651858.CD010456.pub2. http://www.ncbi.nlm.nih.gov/pubmed/25032820.

166.     Beggs S, Foong YC, Le HC, et al. Swimming training for asthma in children and adolescents aged 18 years and under. Cochrane Database Syst Rev 2013; 4:CD009607. DOI: 10.1002/14651858.CD009607.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23633375.

167.     Bonini M, Di Mambro C, Calderon MA, et al. Beta(2)-agonists for exercise-induced asthma. Cochrane Database Syst Rev 2013; 10:CD003564. DOI: 10.1002/14651858.CD003564.pub3. http://www.ncbi.nlm.nih.gov/pubmed/24089311.

168.     Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update-2016. J Allergy Clin Immunol. 2016; 138(5):1292–5. DOI: 10.1016/j.jaci.2016.05.029. http://www.ncbi.nlm.nih.gov/pubmed/27665489.

169.     Pinnock H, Epiphaniou E, Pearce G, et al. Implementing supported self-management for asthma: A systematic review and suggested hierarchy of evidence of implementation studies. BMC Med 2015; 13:127. DOI: 10.1186/s12916-015-0361-0. http://www.ncbi.nlm.nih.gov/pubmed/26032941.

170.     Denford S, Taylor RS, Campbell JL, et al. Effective behavior change techniques in asthma self-care interventions: Systematic review and meta-regression. Health Psychol. 2014; 33(7):577–87. DOI: 10.1037/a0033080. http://www.ncbi.nlm.nih.gov/pubmed/23815765.

171.     Kirk S, Beatty S, Callery P, et al. The effectiveness of self-care support interventions for children and young people with long-term conditions: A systematic review. Child Care Health Dev 2013; 39(3):305–24. DOI: 10.1111/j.1365-2214.2012.01395.x. http://www.ncbi.nlm.nih.gov/pubmed/22676438.

172.     Marcano Belisario JS, Huckvale K, Greenfield G, et al. Smartphone and tablet self management apps for asthma. Cochrane Database Syst Rev 2013; 11:CD010013. DOI: 10.1002/14651858.CD010013.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24282112.

173.     T J de, Gurol-Urganci I, Vodopivec-Jamsek V, et al. Mobile phone messaging for facilitating self-management of long-term illnesses. Cochrane Database Syst Rev 2012; 12:CD007459. DOI: 10.1002/14651858.CD007459.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23235644.

174.     Blakemore A, Dickens C, Anderson R, et al. Complex interventions reduce use of urgent healthcare in adults with asthma: Systematic review with meta-regression. Respir Med 2015; 109(2):147–56. DOI: 10.1016/j.rmed.2014.11.002. http://www.ncbi.nlm.nih.gov/pubmed/25433953.

175.     Boyd M, Lasserson TJ, McKean MC, et al. Interventions for educating children who are at risk of asthma-related emergency department attendance. Cochrane Database Syst Rev 2009(2):CD001290. DOI: 10.1002/14651858.CD001290.pub2. http://www.ncbi.nlm.nih.gov/pubmed/19370563.

176.     Bailey EJ, Cates CJ, Kruske SG, et al. Culture-specific programs for children and adults from minority groups who have asthma. Cochrane Database Syst Rev 2009(2):CD006580. DOI: 10.1002/14651858.CD006580.pub4. http://www.ncbi.nlm.nih.gov/pubmed/19370643.

177.     Welsh EJ, Hasan M, Li P. Home-based educational interventions for children with asthma. Cochrane Database Syst Rev 2011(10):CD008469. DOI: 10.1002/14651858.CD008469.pub2. http://www.ncbi.nlm.nih.gov/pubmed/21975783.

178.     Quinones AR, Richardson J, Freeman M, et al. Educational group visits for the management of chronic health conditions: A systematic review. Patient Educ Couns. 2014; 95(1):3–29. DOI: 10.1016/j.pec.2013.12.021. http://www.ncbi.nlm.nih.gov/pubmed/24468199.

179.     Chang AB, Taylor B, Masters IB, et al. Indigenous healthcare worker involvement for Indigenous adults and children with asthma. Cochrane Database Syst Rev 2010(5):CD006344. DOI: 10.1002/14651858.CD006344.pub3. http://www.ncbi.nlm.nih.gov/pubmed/20464742.

180.     Keim-Malpass J, Letzkus LC, Kennedy C. Parent/caregiver health literacy among children with special health care needs: A systematic review of the literature. BMC Pediatr. 2015; 15:92. DOI: 10.1186/s12887-015-0412-x. http://www.ncbi.nlm.nih.gov/pubmed/26242306.

181.     Gibson PG, Powell H, Coughlan J, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003(1):CD001117. http://www.ncbi.nlm.nih.gov/pubmed/12535399.

182.     Coulter A, Entwistle VA, Eccles A, et al. Personalised care planning for adults with chronic or long-term health conditions. Cochrane Database Syst Rev 2015; 3:CD010523. DOI: 10.1002/14651858.CD010523.pub2. http://www.ncbi.nlm.nih.gov/pubmed/25733495.

183.     Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme, Groos S, Kretschmann J, et al. Qualitätssicherungsbericht 2015. Disease-Management-Programme in Nordrhein. 2015 [cited: 2017-09-19]. http://www.kvno.de/downloads/quali/qualbe_dmp15.pdf.

184.     Kassenärztliche Bundesvereinigung (KBV). Disease-Management-Programm Asthma bronchiale – Qualitätszielerreichung 2015. 2017 [cited: 2018-01-03]. http://www.kbv.de/media/sp/DMP_Asthma_Ergebnisse_QS.pdf.

185.     Worth H, Schacher C, Deutsche Atemwegsliga. Persönlicher Asthma-Aktionsplan auf Grundlage des NASA-Schulungsprogramms. 2016 [cited: 2018-03-12]. http://www.atemwegsliga.de/asthma.html?file=tl_files/eigene-dateien/Train-The-Trainer/Aktionsplan%20Asthma.pdf.

186.     Freitas DA, Holloway EA, Bruno SS, et al. Breathing exercises for adults with asthma. Cochrane Database Syst Rev 2013; 10:CD001277. DOI: 10.1002/14651858.CD001277.pub3. http://www.ncbi.nlm.nih.gov/pubmed/24085551.

187.     Barker NJ, Jones M, O’Connell NE, et al. Breathing exercises for dysfunctional breathing/hyperventilation syndrome in children. Cochrane Database Syst Rev 2013; 12:CD010376. DOI: 10.1002/14651858.CD010376.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24347088.

188.     Silva IS, Fregonezi GA, Dias FA, et al. Inspiratory muscle training for asthma. Cochrane Database Syst Rev 2013; 9:CD003792. DOI: 10.1002/14651858.CD003792.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24014205.

189.     Macedo TM, Freitas DA, Chaves GS, et al. Breathing exercises for children with asthma. Cochrane Database Syst Rev 2016; 4:CD011017. DOI: 10.1002/14651858.CD011017.pub2. http://www.ncbi.nlm.nih.gov/pubmed/27070225.

190.     Scholten-Peeters GG, Thoomes E, Konings S, et al. Is manipulative therapy more effective than sham manipulation in adults: A systematic review and meta-analysis. Chiropr Man Therap 2013; 21(1):34. DOI: 10.1186/2045-709X-21-34. http://www.ncbi.nlm.nih.gov/pubmed/24274314.

191.     Dennis JA, Cates CJ. Alexander technique for chronic asthma. Cochrane Database Syst Rev 2012(9):CD000995. DOI: 10.1002/14651858.CD000995.pub2. http://www.ncbi.nlm.nih.gov/pubmed/22972048.

192.     Cicchitti L, Martelli M, Cerritelli F. Chronic inflammatory disease and osteopathy: A systematic review. PLoS. One. 2015; 10(3):e0121327. DOI: 10.1371/journal.pone.0121327. http://www.ncbi.nlm.nih.gov/pubmed/25781621.

193.     Posadzki P, Lee MS, Ernst E. Osteopathic manipulative treatment for pediatric conditions: A systematic review. Pediatrics 2013; 132(1):140–52. DOI: 10.1542/peds.2012-3959. http://www.ncbi.nlm.nih.gov/pubmed/23776117.

194.     Wang Z, May SM, Charoenlap S, et al. Effects of secondhand smoke exposure on asthma morbidity and health care utilization in children: A systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2015; 115(5):396–401. DOI: 10.1016/j.anai.2015.08.005. http://www.ncbi.nlm.nih.gov/pubmed/26411971.

195.     Frazer K, Callinan JE, McHugh J, et al. Legislative smoking bans for reducing harms from secondhand smoke exposure, smoking prevalence and tobacco consumption. Cochrane Database Syst Rev 2016; 2:CD005992. DOI: 10.1002/14651858.CD005992.pub3. http://www.ncbi.nlm.nih.gov/pubmed/26842828.

196.     Been JV, Nurmatov UB, Cox B, et al. Effect of smoke-free legislation on perinatal and child health: A systematic review and meta-analysis. Lancet 2014; 383(9928):1549–60. DOI: 10.1016/S0140-6736(14)60082-9. http://www.ncbi.nlm.nih.gov/pubmed/24680633.

197.     Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie (DG-Sucht), et al. S3-Leitlinie „Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsums“. AWMF-Register Nr. 076-006. (Stand: 09.02.2015). 2014 [cited: 2018-09-13]. http://www.awmf.org/uploads/tx_szleitlinien/076-006l_S3_Tabak_2015-02.pdf.

198.     Easter G, Sharpe L, Hunt CJ. Systematic Review and Meta-Analysis of Anxious and Depressive Symptoms in Caregivers of Children With Asthma. J Pediatr Psychol 2015; 40(7):623–32. DOI: 10.1093/jpepsy/jsv012. http://www.ncbi.nlm.nih.gov/pubmed/25829528.

199.     Ferro MA, Boyle MH. Self-concept among youth with a chronic illness: A meta-analytic review. Health Psychol. 2013; 32(8):839–48. DOI: 10.1037/a0031861. http://www.ncbi.nlm.nih.gov/pubmed/23477575.

200.     Gao YH, Zhao HS, Zhang FR, et al. The Relationship between Depression and Asthma: A Meta-Analysis of Prospective Studies. PLoS. One. 2015; 10(7):e0132424. DOI: 10.1371/journal.pone.0132424. http://www.ncbi.nlm.nih.gov/pubmed/26197472.

201.     Blakeley C, Blakemore A, Hunter C, et al. Does anxiety predict the use of urgent care by people with long term conditions? A systematic review with meta-analysis. J Psychosom Res 2014; 77(3):232–9. DOI: 10.1016/j.jpsychores.2014.06.010. http://www.ncbi.nlm.nih.gov/pubmed/25149033.

202.     Eccleston C, Fisher E, Law E, et al. Psychological interventions for parents of children and adolescents with chronic illness. Cochrane Database Syst Rev 2015; 4:CD009660. DOI: 10.1002/14651858.CD009660.pub3. http://www.ncbi.nlm.nih.gov/pubmed/25874881.

203.     Lv N, Xiao L, Ma J. Weight Management Interventions in Adult and Pediatric Asthma Populations: A Systematic Review. J Pulm. Respir Med 2015; 5(232):1000232. DOI: 10.4172/2161-105X.1000232. http://www.ncbi.nlm.nih.gov/pubmed/26413417.

204.     Adeniyi FB, Young T. Weight loss interventions for chronic asthma. Cochrane Database Syst Rev 2012(7):CD009339. DOI: 10.1002/14651858.CD009339.pub2. http://www.ncbi.nlm.nih.gov/pubmed/22786526.

205.     Plaschke P, Janson C, Balder B, et al. Adult asthmatics sensitized to cats and dogs: Symptoms, severity, and bronchial hyperresponsiveness in patients with furred animals at home and patients without these animals. Allergy 1999; 54(8):843–50. http://www.ncbi.nlm.nih.gov/pubmed/10485388.

206.     Lewis SA, Weiss ST, Platts-Mills TA, et al. The role of indoor allergen sensitization and exposure in causing morbidity in women with asthma. Am J Respir Crit Care Med 2002; 165(7):961–6. http://www.ncbi.nlm.nih.gov/pubmed/11934722.

207.     Arroyave WD, Rabito FA, Carlson JC, et al. Impermeable dust mite covers in the primary and tertiary prevention of allergic disease: A meta-analysis. Ann Allergy Asthma Immunol. 2014; 112(3):237–48. DOI: 10.1016/j.anai.2014.01.006. http://www.ncbi.nlm.nih.gov/pubmed/24484971.

208.     Murray CS, Foden P, Sumner H, et al. Preventing Severe Asthma Exacerbations in Children. A Randomized Trial of Mite-Impermeable Bedcovers. Am J Respir Crit Care Med 2017; 196(2):150–8. DOI: 10.1164/rccm.201609-1966OC. http://www.ncbi.nlm.nih.gov/pubmed/28282501.

209.     Leas BF, D’Anci KE, Apter AJ, et al. Effectiveness of Indoor Allergen Reduction in Management of Asthma. 2018 (AHRQ Publication; 18-EHC002-EF) [cited: 2018-05-28]. DOI: 10.23970/AHRQEPCCER201. http://effectivehealthcare.ahrq.gov/sites/default/files/pdf/cer-201-indoor-allergen-reduction-asthma_3.pdf.

210.     Sharpe RA, Bearman N, Thornton CR, et al. Indoor fungal diversity and asthma: A meta-analysis and systematic review of risk factors. J Allergy Clin Immunol. 2015; 135(1):110–22. DOI: 10.1016/j.jaci.2014.07.002. http://www.ncbi.nlm.nih.gov/pubmed/25159468.

211.     Sauni R, Verbeek JH, Uitti J, et al. Remediating buildings damaged by dampness and mould for preventing or reducing respiratory tract symptoms, infections and asthma. Cochrane Database Syst Rev 2015; 2:CD007897. DOI: 10.1002/14651858.CD007897.pub3. http://www.ncbi.nlm.nih.gov/pubmed/25715323.

212.     Singh M, Jaiswal N. Dehumidifiers for chronic asthma. Cochrane Database Syst Rev 2013; 6:CD003563. DOI: 10.1002/14651858.CD003563.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23760885.

213.     Fan J, Li S, Fan C, et al. The impact of PM2.5 on asthma emergency department visits: A systematic review and meta-analysis. Environ Sci Pollut. Res Int 2016; 23(1):843–50. DOI: 10.1007/s11356-015-5321-x. http://www.ncbi.nlm.nih.gov/pubmed/26347419.

214.     Zheng XY, Ding H, Jiang LN, et al. Association between Air Pollutants and Asthma Emergency Room Visits and Hospital Admissions in Time Series Studies: A Systematic Review and Meta-Analysis. PLoS. One. 2015; 10(9):e0138146. DOI: 10.1371/journal.pone.0138146. http://www.ncbi.nlm.nih.gov/pubmed/26382947.

215.     Zhao J, Zhai YK, Zhu WJ, et al. Effectiveness of Telemedicine for Controlling Asthma Symptoms: A Systematic Review and Meta-analysis. Telemed. J E Health 2015; 21(6):484–92. DOI: 10.1089/tmj.2014.0119. http://www.ncbi.nlm.nih.gov/pubmed/25393915.

216.     DiBello K, Boyar K, Abrenica S, et al. The effectiveness of text messaging programs on adherence to treatment regimens among adults aged 18 to 45 years diagnosed with asthma: A systematic review (Provisional abstract). JBI Database of Systematic Reviews & Implementation Reports 2014; 12(4):485–532.

217.     Hieftje K, Edelman EJ, Camenga DR, et al. Electronic media-based health interventions promoting behavior change in youth: A systematic review. JAMA Pediatr 2013; 167(6):574–80. DOI: 10.1001/jamapediatrics.2013.1095. http://www.ncbi.nlm.nih.gov/pubmed/23568703.

218.     McLean S, Chandler D, Nurmatov U, et al. Telehealthcare for asthma. Cochrane Database Syst Rev 2010(10):CD007717. DOI: 10.1002/14651858.CD007717.pub2. http://www.ncbi.nlm.nih.gov/pubmed/20927763.

219.     Torrego A, Sola I, Munoz AM, et al. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev 2014; 3:CD009910. DOI: 10.1002/14651858.CD009910.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24585221.

220.     Blue Cross Blue Shield Association (BCBS). Bronchial thermoplasty for treatment of inadequately controlled severe asthma. 2014 [cited: 2017-01-11]. http://etsad.fr/etsad/afficher_lien.php?id=5618.

221.     Peytremann-Bridevaux I, Arditi C, Gex G, et al. Chronic disease management programmes for adults with asthma. Cochrane Database Syst Rev 2015; 5:CD007988. DOI: 10.1002/14651858.CD007988.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26014500.

222.     Mohammed MA, Moles RJ, Chen TF. Impact of Pharmaceutical Care Interventions on Health-Related Quality-of-Life Outcomes: A Systematic Review and Meta-analysis. Ann Pharmacother 2016; 50(10):862–81. DOI: 10.1177/1060028016656016. http://www.ncbi.nlm.nih.gov/pubmed/27363846.

223.     Bundesministerium für Gesundheit und soziale Sicherung (BMGS). Sozialgesetzbuch (SGB) Fünftes Buch (V) - Gesetzliche Krankenversicherung - (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGBl. I S. 2477). § 40 Leistungen zur medizinischen Rehabilitation. 1988 [cited: 2017-10-24]. http://www.gesetze-im-internet.de/sgb_5/__40.html.

zurück nach oben


Zurück zum Anhang

zuletzt verändert: 05.03.2019 16:22